infectious virus titering
How to titer retrovirus/lentivirus
A number of methods have been developed for determining the lentiviral/retroviral titers such as using ELISA to assess the amount of p24 antigen, enzyme assay to quantify reverse transcriptase activity, and real time RT-PCR to count viral RNA genome. However, these methods do not differentiate non-infectious from infectious virus particles that are present in the virus preparation; therefore, these measurements rely on some correlation factors to derive a titer, which can be inaccurate.
Because an accurate virus titer is critical for most experimental purposes, Allele Biotech’ pre-packaged viruses are measured by the number of genomic integration events to determine the infectious titer. This functional titering is done by first transducing TE671cells (selected for consistent transduction efficiency) followed by measuring the viral genome integrated into the cell genome with QPCR. The number of cellular genome copies is also measured, and the copy number of viruses is divided by that of cells to obtain active virus titer.
A plot of quantitative PCR (Q-PCR) titering of virus preparation is provided above.
TE671 cells (1×105) were transduced with 2×10-3ml of a virus sample to be titered. Cells were harvested and DNA extracted for QPCR. The titer is determined as followed, transduction unit per ml (TU/ml)=N [X1/(X2/2)]/2×10-3ml, where N is the cell number, X1 is the copy number of integrated virus DNA, and X2 is the copy number of GAPDH DNA.
-
New Product of the Week 120610-121310:
CR4(Oct3/4)-ResponseElement-mClavGR2 Reporter Pre-packaged Lentivirus. Shows Oct3/4 target gene transcription by following a photoconvertible FP in real time. Product-on-demand. Email iPS@allelebiotech.com for details.
-
Promotion of the Wee 120610-121310:
Buy one FRET oligo at $200 (50nmol HPLC purified), get the second at half price. Email order to oligo@allelebiotech.com with code AB120710SO.
Categories
- Allele Mail Bag
- cGMP
- Customer Feedback
- Fluorescent proteins
- iPSCs and other stem cells
- nAb: Camelid Antibodies, Nanobodies, VHH
- Next Generation Sequencing (NextGen Seq)
- NIH Budget and You
- oligos and cloning
- Open Forum
- RNAi patent landscape
- SBIR and Business issues
- State of Research
- Synthetic biology
- Uncategorized
- Viruses and cells
- You have the power
Archives
- October 2018
- April 2018
- March 2018
- January 2018
- October 2017
- September 2017
- August 2017
- March 2017
- February 2017
- January 2017
- November 2016
- September 2016
- August 2016
- July 2016
- June 2016
- May 2016
- April 2016
- February 2016
- October 2015
- September 2015
- August 2015
- June 2015
- March 2015
- January 2015
- December 2014
- March 2014
- February 2014
- January 2014
- December 2013
- November 2013
- October 2013
- September 2013
- August 2013
- July 2013
- June 2013
- May 2013
- April 2013
- March 2013
- January 2013
- December 2012
- November 2012
- October 2012
- September 2012
- August 2012
- July 2012
- May 2012
- April 2012
- February 2012
- January 2012
- December 2011
- November 2011
- October 2011
- September 2011
- August 2011
- July 2011
- June 2011
- May 2011
- April 2011
- March 2011
- February 2011
- January 2011
- December 2010
- November 2010
- October 2010
- September 2010
- August 2010
- July 2010
- June 2010
- May 2010
- April 2010
- March 2010
- February 2010
- January 2010
- December 2009
- November 2009
- October 2009
- September 2009
- August 2009
- July 2009
- June 2009
- May 2009
- April 2009
- March 2009
- February 2009
- January 2009
- December 2008
- October 2008
- August 2008
- July 2008